Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.
Coherus Oncology, Inc. Common Stock (CHRS) has a market cap of $269.80M with year-over-year revenue growth of +3.8%. Net margin stands at 10.7%. The stock trades at a P/E ratio of 9.5.
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, CHRS posted revenue growth of +3.8% and trades at a P/E of 9.5.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.